Bioventus (BVS) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bioventus in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BVS, but not buy additional shares or sell existing shares.
View BVS analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 1-year target prices for Bioventus' shares. Their BVS share price forecasts range from $5.00 to $6.00. On average, they expect the company's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 92.1% from the stock's current price.
View analysts price targets for BVS or view top-rated stocks among Wall Street analysts.

Bioventus' stock was trading at $2.61 at the start of the year. Since then, BVS stock has increased by 13.0% and is now trading at $2.95.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 20th 2023.
View our BVS earnings forecast.

Bioventus Inc. (NYSE:BVS) issued its quarterly earnings results on Tuesday, August, 8th. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.11. The business had revenue of $137.07 million for the quarter, compared to the consensus estimate of $128.90 million. Bioventus had a negative net margin of 55.42% and a positive trailing twelve-month return on equity of 1.24%.

Bioventus updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of -$0.24--$0.20 for the period, compared to the consensus estimate of -$0.22. The company issued revenue guidance of $490.00 million-$505.00 million, compared to the consensus revenue estimate of $493.14 million.

(BVS) raised $126 million in an initial public offering on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity served as the underwriters for the IPO.

Bioventus trades on the New York Stock Exchange (NYSE) under the ticker symbol "BVS."

Bioventus' stock is owned by a variety of institutional and retail investors. Top institutional investors include Juniper Investment Company LLC (8.51%), Kent Lake Capital LLC (1.15%), BlackRock Inc. (0.60%), Western Standard LLC (0.51%), Geode Capital Management LLC (0.44%) and Stephens Inc. AR (0.35%). Insiders that own company stock include Anthony D'adamio, Anthony P Bihl III, John A Bartholdson, John Nosenzo, Juniper Investment Company, Ll, Katrina J Church, Kenneth Michael Reali, Mark Leonard Singleton and William A Hawkins.
View institutional ownership trends.

Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BVS stock can currently be purchased for approximately $2.95.

Bioventus (NYSE:BVS) has a market capitalization of $231.81 million and generates $510.62 million in revenue each year. The company earns $-158,700,000.00 in net income (profit) each year or ($4.58) on an earnings per share basis.

The company employs 1,120 workers across the globe.

Bioventus' mailing address is 4721 EMPEROR BOULEVARD SUITE 100, DURHAM NC, 27703. The official website for the company is www.bioventus.com. The company can be reached via phone at 919-474-6700 or via email at investor.relations@bioventus.com.